<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">28218309</PMID><DateCompleted><Year>2018</Year><Month>10</Month><Day>29</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><PubDate><Year>2017</Year><Month>Feb</Month><Day>20</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Suramin interacts with the positively charged region surrounding the 5-fold axis of the EV-A71 capsid and inhibits multiple enterovirus A.</ArticleTitle><Pagination><StartPage>42902</StartPage><MedlinePgn>42902</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">42902</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/srep42902</ELocationID><Abstract><AbstractText>Suramin was previously shown to bind to the EV-A71 capsid through its naphthalenetrisulfonic acid groups, thereby reducing virus-cell binding and inhibiting viral replication. Here, we identify VP1-145 as the critical amino acid that accounts for the differential sensitivity of EVA-71 viruses to suramin. A single Q or G to E substitution at VP1-145 results in an approximately 30-fold shift of IC<sub>50</sub> or IC<sub>90</sub> values reproducing the inhibition profile observed with field isolates expressing either the 145Q or E mutation. Our data support the conclusion that suramin binds to the positively charged region surrounding the 5-fold axis of the capsid and consequently blocks the virus attachment and entry into host cells. In order to assess the antiviral-spectrum of suramin, we analyzed 18 representative enteroviruses: A (n&#x2009;=&#x2009;7), B (n&#x2009;=&#x2009;5), C (n&#x2009;=&#x2009;5) and D (n&#x2009;=&#x2009;1). We show that suramin potency is restricted to enterovirus A species. Clinical development of suramin is further supported by pharmacokinetic data demonstrating bioactive plasma levels after a single dose intramuscular administration in macaques. Altogether, our findings support the clinical development of suramin as a novel entry inhibitor for the treatment of enterovirus A infections.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ren</LastName><ForeName>Peijun</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Unit of Anti-infective Research, Institut Pasteur of Shanghai, Chinese Academy of Sciences, 320 Yueyang Road, 200031, Shanghai, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Viral Pathogenesis, Institut Pasteur, 28 Rue du Docteur Roux, 75724, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Yimei</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Unit of Anti-infective Research, Institut Pasteur of Shanghai, Chinese Academy of Sciences, 320 Yueyang Road, 200031, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Wenqi</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>HONZ Pharma, 26FL, Dongshan Square, 69 Xian Lie Zhong Rd, 510095, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hong</LastName><ForeName>Liping</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>HONZ Pharma, 26FL, Dongshan Square, 69 Xian Lie Zhong Rd, 510095, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Delpeyroux</LastName><ForeName>Fran&#xe7;is</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Unit of Biology of Enteric Viruses, Institut Pasteur, 25 Rue du Docteur Roux, 75724, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>INSERM U994, Institut National de Sant&#xe9; et de La Recherche M&#xe9;dicale, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arenzana-Seisdedos</LastName><ForeName>Fernando</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Laboratory of Viral Pathogenesis, Institut Pasteur, 28 Rue du Docteur Roux, 75724, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Altmeyer</LastName><ForeName>Ralf</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Unit of Anti-infective Research, Institut Pasteur of Shanghai, Chinese Academy of Sciences, 320 Yueyang Road, 200031, Shanghai, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Shandong University-Helmholtz Institute of Biotechnology, 168 Zhuzhou Road, 266101, Qingdao, Shandong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Qingdao Municipal Center for Disease Control &amp;Prevention, 175 Shandong Road, 266033, Qingdao, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>02</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D036022">Capsid Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>6032D45BEM</RegistryNumber><NameOfSubstance UI="D013498">Suramin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D036022" MajorTopicYN="N">Capsid Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004770" MajorTopicYN="N">Enterovirus</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006207" MajorTopicYN="N">Half-Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008252" MajorTopicYN="N">Macaca fascicularis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016296" MajorTopicYN="N">Mutagenesis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010802" MajorTopicYN="N">Phylogeny</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013498" MajorTopicYN="N">Suramin</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014709" MajorTopicYN="N">Vero Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>R.A. and P.R. are named inventors of a patent covering suramin for treating viral disease (appl. no. 201310077649.9, PCT/CN2013/072402). HONZ Pharma is the patentee of a patent application covering suramin for treating viral disease (appl. no. 201310077649.9, PCT/CN2013/072402). L.H. is the VP of HONZ Pharma, and W.W. is an employee of HONZ Pharma. The other authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>4</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>1</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>2</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>2</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>10</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>2</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28218309</ArticleId><ArticleId IdType="pmc">PMC5317167</ArticleId><ArticleId IdType="doi">10.1038/srep42902</ArticleId><ArticleId IdType="pii">srep42902</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Zeng M. et al.. Seroepidemiology of Enterovirus 71 infection prior to the 2011 season in children in Shanghai. J Clin Virol 53, 285&#x2013;289, doi: 10.1016/j.jcv.2011.12.025 (2012).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2011.12.025</ArticleId><ArticleId IdType="pubmed">22265829</ArticleId></ArticleIdList></Reference><Reference><Citation>Xing W. et al.. Hand, foot, and mouth disease in China, 2008&#x2013;12: an epidemiological study. The Lancet Infectious Diseases 14, 308&#x2013;318 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4035015</ArticleId><ArticleId IdType="pubmed">24485991</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Y. F. et al.. Complete Genome Analysis of Coxsackievirus A2, A4, A5, and A10 Strains Isolated from Hand, Foot, and Mouth Disease Patients in China Revealing Frequent Recombination of Human Enterovirus A. Journal of Clinical Microbiology 49, 2426&#x2013;2434, doi: 10.1128/jcm.00007-11 (2011).</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jcm.00007-11</ArticleId><ArticleId IdType="pmc">PMC3147834</ArticleId><ArticleId IdType="pubmed">21543560</ArticleId></ArticleIdList></Reference><Reference><Citation>Oberste M. S. et al.. Enteroviruses 76, 89, 90 and 91 represent a novel group within the species Human enterovirus A. Journal of General Virology 86, 445&#x2013;451, doi: 10.1099/vir.0.80475-0 (2005).</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/vir.0.80475-0</ArticleId><ArticleId IdType="pubmed">15659764</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramirez-Fort M. K. et al.. Coxsackievirus A6 associated hand, foot and mouth disease in adults: Clinical presentation and review of the literature. Journal of Clinical Virology 60, 381&#x2013;386, doi: 10.1016/j.jcv.2014.04.023 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2014.04.023</ArticleId><ArticleId IdType="pubmed">24932735</ArticleId></ArticleIdList></Reference><Reference><Citation>Dotta F. &amp; Sebastiani G. Enteroviral Infections and Development of Type 1 Diabetes: The Brothers Karamazov Within the CVBs. Diabetes 63, 384&#x2013;386, doi: 10.2337/db13-1441 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/db13-1441</ArticleId><ArticleId IdType="pubmed">24464713</ArticleId></ArticleIdList></Reference><Reference><Citation>Tyler K. L. RAtionale for the evaluation of fluoxetine in the treatment of enterovirus d68-associated acute flaccid myelitis. JAMA Neurology 72, 493&#x2013;494, doi: 10.1001/jamaneurol.2014.4625 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2014.4625</ArticleId><ArticleId IdType="pmc">PMC5086417</ArticleId><ArticleId IdType="pubmed">25775436</ArticleId></ArticleIdList></Reference><Reference><Citation>Tokarz R. et al.. Worldwide emergence of multiple clades of enterovirus 68. Journal of General Virology 93, 1952&#x2013;1958, doi: 10.1099/vir.0.043935-0 (2012).</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/vir.0.043935-0</ArticleId><ArticleId IdType="pmc">PMC3542132</ArticleId><ArticleId IdType="pubmed">22694903</ArticleId></ArticleIdList></Reference><Reference><Citation>Webster A. D. Pleconaril-an advance in the treatment of enteroviral infection in immuno-compromised patients. J Clin Virol 32, 1&#x2013;6, doi: 10.1016/j.jcv.2004.06.006 (2005).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2004.06.006</ArticleId><ArticleId IdType="pmc">PMC7108213</ArticleId><ArticleId IdType="pubmed">15571999</ArticleId></ArticleIdList></Reference><Reference><Citation>Tijsma A. et al.. The Capsid Binder Vapendavir and the Novel Protease Inhibitor SG85 Inhibit Enterovirus 71 Replication. Antimicrobial Agents and Chemotherapy 58, 6990&#x2013;6992, doi: 10.1128/aac.03328-14 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/aac.03328-14</ArticleId><ArticleId IdType="pmc">PMC4249361</ArticleId><ArticleId IdType="pubmed">25199773</ArticleId></ArticleIdList></Reference><Reference><Citation>Plevka P. et al.. Structure of human enterovirus 71 in complex with a capsid-binding inhibitor. Proc Natl Acad Sci USA 110, 5463&#x2013;5467, doi: 10.1073/pnas.1222379110 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1222379110</ArticleId><ArticleId IdType="pmc">PMC3619292</ArticleId><ArticleId IdType="pubmed">23509286</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren P. et al.. The approved pediatric drug suramin identified as a clinical candidate for the treatment of EV71 infection[mdash]suramin inhibits EV71 infection in vitro and in vivo. Emerg Microbes Infect 3, e62, doi: 10.1038/emi.2014.60 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/emi.2014.60</ArticleId><ArticleId IdType="pmc">PMC4185360</ArticleId><ArticleId IdType="pubmed">26038755</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan C. W., Poh C. L., Sam I.-C. &amp; Chan Y. F. Enterovirus 71 Uses Cell Surface Heparan Sulfate Glycosaminoglycan as an Attachment Receptor. Journal of Virology 87, 611&#x2013;620, doi: 10.1128/jvi.02226-12 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.02226-12</ArticleId><ArticleId IdType="pmc">PMC3536405</ArticleId><ArticleId IdType="pubmed">23097443</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., Qing J., Sun Y. &amp; Rao Z. Suramin inhibits EV71 infection. Antiviral research 103, 1&#x2013;6, doi: 10.1016/j.antiviral.2013.12.008 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2013.12.008</ArticleId><ArticleId IdType="pubmed">24374150</ArticleId></ArticleIdList></Reference><Reference><Citation>Arita M., Wakita T. &amp; Shimizu H. Characterization of pharmacologically active compounds that inhibit poliovirus and enterovirus 71 infectivity. Journal of General Virology 89, 2518&#x2013;2530, doi: 10.1099/vir.0.2008/002915-0 (2008).</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/vir.0.2008/002915-0</ArticleId><ArticleId IdType="pubmed">18796721</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y. et al.. Peptidyl Aldehyde NK-1.8k Suppresses Enterovirus 71 and Enterovirus 68 Infection by Targeting Protease 3C. Antimicrobial Agents and Chemotherapy 59, 2636&#x2013;2646, doi: 10.1128/aac.00049-15 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/aac.00049-15</ArticleId><ArticleId IdType="pmc">PMC4394787</ArticleId><ArticleId IdType="pubmed">25691647</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu G. et al.. Enterovirus 71 and Coxsackievirus A16 3C Proteases: Binding to Rupintrivir and Their Substrates and Anti-Hand, Foot, and Mouth Disease Virus Drug Design. Journal of Virology 85, 10319&#x2013;10331, doi: 10.1128/jvi.00787-11 (2011).</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.00787-11</ArticleId><ArticleId IdType="pmc">PMC3196414</ArticleId><ArticleId IdType="pubmed">21795339</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J. et al.. Crystal Structures of Enterovirus 71 3C Protease Complexed with Rupintrivir Reveal the Roles of Catalytically Important Residues. Journal of Virology 85, 10021&#x2013;10030, doi: 10.1128/jvi.05107-11 (2011).</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.05107-11</ArticleId><ArticleId IdType="pmc">PMC3196404</ArticleId><ArticleId IdType="pubmed">21813612</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X. et al.. Rupintrivir is a promising candidate for treating severe cases of enterovirus-71 infection: Evaluation of antiviral efficacy in a murine infection model. Antiviral Research 97, 264&#x2013;269, doi: 10.1016/j.antiviral.2012.12.029 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2012.12.029</ArticleId><ArticleId IdType="pubmed">23295352</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C.-Y. et al.. Antiviral Potential of a Novel Compound CW-33 against Enterovirus A71 via Inhibition of Viral 2A Protease. Viruses 7, 2764, doi: 10.3390/v7062764 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v7062764</ArticleId><ArticleId IdType="pmc">PMC4488731</ArticleId><ArticleId IdType="pubmed">26090728</ArticleId></ArticleIdList></Reference><Reference><Citation>Falah N. et al.. Blocking human enterovirus 71 replication by targeting viral 2A protease. Journal of Antimicrobial Chemotherapy 67, 2865&#x2013;2869, doi: 10.1093/jac/dks304 (2012).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/dks304</ArticleId><ArticleId IdType="pubmed">22865380</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J. et al.. Lycorine reduces mortality of human enterovirus 71-infected mice by inhibiting virus replication. Virology Journal 8, 483 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3212826</ArticleId><ArticleId IdType="pubmed">22029605</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao Q. et al.. Discovery of Itraconazole with Broad-Spectrum In Vitro Antienterovirus Activity That Targets Nonstructural Protein 3A. Antimicrobial Agents and Chemotherapy 59, 2654&#x2013;2665, doi: 10.1128/aac.05108-14 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/aac.05108-14</ArticleId><ArticleId IdType="pmc">PMC4394834</ArticleId><ArticleId IdType="pubmed">25691649</ArticleId></ArticleIdList></Reference><Reference><Citation>Strating J. R. et al.. Itraconazole inhibits enterovirus replication by targeting the oxysterol-binding protein. Cell Rep 10, 600&#x2013;615, doi: 10.1016/j.celrep.2014.12.054 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2014.12.054</ArticleId><ArticleId IdType="pmc">PMC4383725</ArticleId><ArticleId IdType="pubmed">25640182</ArticleId></ArticleIdList></Reference><Reference><Citation>Arita M., Wakita T. &amp; Shimizu H. Cellular kinase inhibitors that suppress enterovirus replication have a conserved target in viral protein 3A similar to that of enviroxime. Journal of General Virology 90, 1869&#x2013;1879, doi: 10.1099/vir.0.012096-0 (2009).</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/vir.0.012096-0</ArticleId><ArticleId IdType="pubmed">19439558</ArticleId></ArticleIdList></Reference><Reference><Citation>Arita M., Takebe Y., Wakita T. &amp; Shimizu H. A bifunctional anti-enterovirus compound that inhibits replication and the early stage of enterovirus 71 infection. Journal of General Virology 91, 2734&#x2013;2744, doi: 10.1099/vir.0.023374-0 (2010).</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/vir.0.023374-0</ArticleId><ArticleId IdType="pubmed">20660150</ArticleId></ArticleIdList></Reference><Reference><Citation>Shang L. et al.. An adenosine nucleoside analogue NITD008 inhibits EV71 proliferation. Antiviral Research 112, 47&#x2013;58, doi: 10.1016/j.antiviral.2014.10.009 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2014.10.009</ArticleId><ArticleId IdType="pubmed">25446894</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng C.-L. et al.. Inhibition of Enterovirus 71 by Adenosine Analog NITD008. Journal of Virology 88, 11915&#x2013;11923, doi: 10.1128/jvi.01207-14 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.01207-14</ArticleId><ArticleId IdType="pmc">PMC4178731</ArticleId><ArticleId IdType="pubmed">25100827</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Linden L. et al.. The RNA Template Channel of the RNA-Dependent RNA Polymerase as a Target for Development of Antiviral Therapy of Multiple Genera within a Virus Family. PLoS Pathog 11, e1004733, doi: 10.1371/journal.ppat.1004733 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1004733</ArticleId><ArticleId IdType="pmc">PMC4370873</ArticleId><ArticleId IdType="pubmed">25799064</ArticleId></ArticleIdList></Reference><Reference><Citation>Thibaut H. J. et al.. Binding of Glutathione to Enterovirus Capsids Is Essential for Virion Morphogenesis. PLoS Pathog 10, e1004039, doi: 10.1371/journal.ppat.1004039 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1004039</ArticleId><ArticleId IdType="pmc">PMC3983060</ArticleId><ArticleId IdType="pubmed">24722756</ArticleId></ArticleIdList></Reference><Reference><Citation>Qing J. et al.. Cyclophilin A Associates with Enterovirus-71 Virus Capsid and Plays an Essential Role in Viral Infection as an Uncoating Regulator. PLoS Pathog 10, e1004422, doi: 10.1371/journal.ppat.1004422 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1004422</ArticleId><ArticleId IdType="pmc">PMC4183573</ArticleId><ArticleId IdType="pubmed">25275585</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura Y. et al.. Human P-selectin glycoprotein ligand-1 is a functional receptor for enterovirus 71. Nat Med 15, 794&#x2013;797, doi: http://www.nature.com/nm/journal/v15/n7/suppinfo/nm.1961_S1.html (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19543284</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura Y., Wakita T. &amp; Shimizu H. Tyrosine Sulfation of the Amino Terminus of PSGL-1 Is Critical for Enterovirus 71 Infection. PLoS Pathog 6, e1001174, doi: 10.1371/journal.ppat.1001174 (2010).</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1001174</ArticleId><ArticleId IdType="pmc">PMC2973824</ArticleId><ArticleId IdType="pubmed">21079683</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura Y. et al.. Enterovirus 71 Binding to PSGL-1 on Leukocytes: VP1-145 Acts as a Molecular Switch to Control Receptor Interaction. PLoS Pathog 9, e1003511, doi: 10.1371/journal.ppat.1003511 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1003511</ArticleId><ArticleId IdType="pmc">PMC3723564</ArticleId><ArticleId IdType="pubmed">23935488</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamayoshi S. et al.. Scavenger receptor B2 is a cellular receptor for enterovirus 71. Nat Med 15, 798&#x2013;801, doi: http://www.nature.com/nm/journal/v15/n7/suppinfo/nm.1992_S1.html (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19543282</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamayoshi S. et al.. Human SCARB2-Dependent Infection by Coxsackievirus A7, A14, and A16 and Enterovirus 71. Journal of Virology 86, 5686&#x2013;5696, doi: 10.1128/jvi.00020-12 (2012).</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.00020-12</ArticleId><ArticleId IdType="pmc">PMC3347270</ArticleId><ArticleId IdType="pubmed">22438546</ArticleId></ArticleIdList></Reference><Reference><Citation>Dang M. et al.. Molecular mechanism of SCARB2-mediated attachment and uncoating of EV71. Protein &amp; Cell 5, 692&#x2013;703, doi: 10.1007/s13238-014-0087-3 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13238-014-0087-3</ArticleId><ArticleId IdType="pmc">PMC4145081</ArticleId><ArticleId IdType="pubmed">24986489</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X. et al.. A sensor-adaptor mechanism for enterovirus uncoating from structures of EV71. Nat Struct Mol Biol advance online publication, doi: http://www.nature.com/nsmb/journal/vaop/ncurrent/abs/nsmb.2255.html#supplementary-information (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3378640</ArticleId><ArticleId IdType="pubmed">22388738</ArticleId></ArticleIdList></Reference><Reference><Citation>Du N. et al.. Cell Surface Vimentin Is an Attachment Receptor for Enterovirus 71. Journal of Virology 88, 5816&#x2013;5833, doi: 10.1128/jvi.03826-13 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.03826-13</ArticleId><ArticleId IdType="pmc">PMC4019121</ArticleId><ArticleId IdType="pubmed">24623428</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang S.-L., Chou Y.-T., Wu C.-N. &amp; Ho M.-S. Annexin II Binds to Capsid Protein VP1 of Enterovirus 71 and Enhances Viral Infectivity. Journal of Virology 85, 11809&#x2013;11820, doi: 10.1128/jvi.00297-11 (2011).</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.00297-11</ArticleId><ArticleId IdType="pmc">PMC3209289</ArticleId><ArticleId IdType="pubmed">21900167</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan S. et al.. Identification of Positively Charged Residues in Enterovirus 71 Capsid Protein VP1 Essential for Production of Infectious Particles. Journal of Virology, doi: 10.1128/jvi.02482-15 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.02482-15</ArticleId><ArticleId IdType="pmc">PMC4702679</ArticleId><ArticleId IdType="pubmed">26512078</ArticleId></ArticleIdList></Reference><Reference><Citation>Makari D., Jensen K. M., Harris B. &amp; Jafri H. S. Randomized, Double-Blind Study of the Safety of the Liquid Versus Lyophilized Formulation of Palivizumab in Premature Infants and Children with Chronic Lung Disease of Prematurity. Infectious Diseases and Therapy 3, 339&#x2013;347, doi: 10.1007/s40121-014-0033-y (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40121-014-0033-y</ArticleId><ArticleId IdType="pmc">PMC4269632</ArticleId><ArticleId IdType="pubmed">25156956</ArticleId></ArticleIdList></Reference><Reference><Citation>Kataoka C. et al.. The Role of VP1 Amino Acid Residue 145 of Enterovirus 71 in Viral Fitness and Pathogenesis in a Cynomolgus Monkey Model. PLoS Pathog 11, e1005033, doi: 10.1371/journal.ppat.1005033 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1005033</ArticleId><ArticleId IdType="pmc">PMC4504482</ArticleId><ArticleId IdType="pubmed">26181772</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan C. W., Sam I. C., Lee V. S., Wong H. V. &amp; Chan Y. F. VP1 residues around the five-fold axis of enterovirus A71 mediate heparan sulfate interaction. Virology 501, 79&#x2013;87, doi: 10.1016/j.virol.2016.11.009 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2016.11.009</ArticleId><ArticleId IdType="pubmed">27875780</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang S.-C. et al.. Genetic characterization of enterovirus 71 isolated from patients with severe disease by comparative analysis of complete genomes. Journal of Medical Virology 84, 931&#x2013;939, doi: 10.1002/jmv.23287 (2012).</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.23287</ArticleId><ArticleId IdType="pubmed">22499017</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaini Z. &amp; McMinn P. A single mutation in capsid protein VP1 (Q145E) of a genogroup C4 strain of human enterovirus 71 generates a mouse-virulent phenotype. Journal of General Virology 93, 1935&#x2013;1940, doi: 10.1099/vir.0.043893-0 (2012).</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/vir.0.043893-0</ArticleId><ArticleId IdType="pubmed">22647370</ArticleId></ArticleIdList></Reference><Reference><Citation>Gardner C. L. et al.. Deliberate Attenuation of Chikungunya Virus by Adaptation to Heparan Sulfate-Dependent Infectivity: A Model for Rational Arboviral Vaccine Design. PLoS Negl Trop Dis 8, e2719, doi: 10.1371/journal.pntd.0002719 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0002719</ArticleId><ArticleId IdType="pmc">PMC3930508</ArticleId><ArticleId IdType="pubmed">24587470</ArticleId></ArticleIdList></Reference><Reference><Citation>Roehrig J. T. et al.. Mutation of the dengue virus type 2 envelope protein heparan sulfate binding sites or the domain III lateral ridge blocks replication in Vero cells prior to membrane fusion. Virology 441, 114&#x2013;125, doi: 10.1016/j.virol.2013.03.011 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2013.03.011</ArticleId><ArticleId IdType="pubmed">23571092</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang J. et al.. Hepatitis C Virus Attachment Mediated by Apolipoprotein E Binding to Cell Surface Heparan Sulfate. Journal of Virology 86, 7256&#x2013;7267, doi: 10.1128/jvi.07222-11 (2012).</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.07222-11</ArticleId><ArticleId IdType="pmc">PMC3416335</ArticleId><ArticleId IdType="pubmed">22532692</ArticleId></ArticleIdList></Reference><Reference><Citation>de Boer S. M. et al.. Heparan Sulfate Facilitates Rift Valley Fever Virus Entry into the Cell. Journal of Virology 86, 13767&#x2013;13771, doi: 10.1128/jvi.01364-12 (2012).</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.01364-12</ArticleId><ArticleId IdType="pmc">PMC3503077</ArticleId><ArticleId IdType="pubmed">23015725</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamura M., Natori K., Kobayashi M., Miyamura T. &amp; Takeda N. Genogroup II Noroviruses Efficiently Bind to Heparan Sulfate Proteoglycan Associated with the Cellular Membrane. Journal of Virology 78, 3817&#x2013;3826, doi: 10.1128/jvi.78.8.3817-3826.2004 (2004).</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.78.8.3817-3826.2004</ArticleId><ArticleId IdType="pmc">PMC374263</ArticleId><ArticleId IdType="pubmed">15047797</ArticleId></ArticleIdList></Reference><Reference><Citation>Trybala E., Liljeqvist J.-&#xc5;., Svennerholm B. &amp; Bergstr&#xf6;m T. Herpes Simplex Virus Types 1 and 2 Differ in Their Interaction with Heparan Sulfate. Journal of Virology 74, 9106&#x2013;9114, doi: 10.1128/jvi.74.19.9106-9114.2000 (2000).</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.74.19.9106-9114.2000</ArticleId><ArticleId IdType="pmc">PMC102109</ArticleId><ArticleId IdType="pubmed">10982357</ArticleId></ArticleIdList></Reference><Reference><Citation>Sureau C. &amp; Salisse J. A conformational heparan sulfate binding site essential to infectivity overlaps with the conserved hepatitis B virus A-determinant. Hepatology 57, 985&#x2013;994, doi: 10.1002/hep.26125 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hep.26125</ArticleId><ArticleId IdType="pubmed">23161433</ArticleId></ArticleIdList></Reference><Reference><Citation>Connell B. J. &amp; Lortat-Jacob H. Human Immunodeficiency Virus and Heparan Sulfate: from attachment to entry inhibition. Frontiers in Immunology 4, doi: 10.3389/fimmu.2013.00385 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2013.00385</ArticleId><ArticleId IdType="pmc">PMC3834540</ArticleId><ArticleId IdType="pubmed">24312095</ArticleId></ArticleIdList></Reference><Reference><Citation>Pourianfar H., Kirk K. &amp; Grollo L. Initial evidence on differences among Enterovirus 71, Coxsackievirus A16 and Coxsackievirus B4 in binding to cell surface heparan sulphate. VirusDis. 25, 277&#x2013;284, doi: 10.1007/s13337-013-0172-x (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13337-013-0172-x</ArticleId><ArticleId IdType="pmc">PMC4188211</ArticleId><ArticleId IdType="pubmed">25674594</ArticleId></ArticleIdList></Reference><Reference><Citation>McLeish N. J., Williams &#xc7;. H., Kaloudas D., Roivainen M. M. &amp; Stanway G. Symmetry-Related Clustering of Positive Charges Is a Common Mechanism for Heparan Sulfate Binding in Enteroviruses. Journal of Virology 86, 11163&#x2013;11170, doi: 10.1128/jvi.00640-12 (2012).</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.00640-12</ArticleId><ArticleId IdType="pmc">PMC3457184</ArticleId><ArticleId IdType="pubmed">22855495</ArticleId></ArticleIdList></Reference><Reference><Citation>Zautner A. E., Jahn B., Hammerschmidt E., Wutzler P. &amp; Schmidtke M. N- and 6-O-Sulfated Heparan Sulfates Mediate Internalization of Coxsackievirus B3 Variant PD into CHO-K1 Cells. Journal of Virology 80, 6629&#x2013;6636, doi: 10.1128/jvi.01988-05 (2006).</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.01988-05</ArticleId><ArticleId IdType="pmc">PMC1488958</ArticleId><ArticleId IdType="pubmed">16775350</ArticleId></ArticleIdList></Reference><Reference><Citation>Israelsson S. et al.. Studies of Echovirus 5 interactions with the cell surface: Heparan sulfate mediates attachment to the host cell. Virus Research 151, 170&#x2013;176, doi: 10.1016/j.virusres.2010.05.001 (2010).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2010.05.001</ArticleId><ArticleId IdType="pubmed">20466025</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodfellow I. G., Sioofy A. B., Powell R. M. &amp; Evans D. J. Echoviruses Bind Heparan Sulfate at the Cell Surface. Journal of Virology 75, 4918&#x2013;4921, doi: 10.1128/jvi.75.10.4918-4921.2001 (2001).</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.75.10.4918-4921.2001</ArticleId><ArticleId IdType="pmc">PMC114248</ArticleId><ArticleId IdType="pubmed">11312365</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura Y. et al.. The Suramin Derivative NF449 Interacts with the 5-fold Vertex of the Enterovirus A71 Capsid to Prevent Virus Attachment to PSGL-1 and Heparan Sulfate. PLOS Pathogens 11, e1005184, doi: 10.1371/journal.ppat.1005184 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1005184</ArticleId><ArticleId IdType="pmc">PMC4592248</ArticleId><ArticleId IdType="pubmed">26430888</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>